Cargando…

Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions

Detalles Bibliográficos
Autores principales:	Greenberg, Barry D., Lemere, Cynthia A., Barnes, Lisa L., Hayden, Kathleen M., Kukull, Walter A., Oh, Esther S., Snyder, Peter J., Supiano, Mark, Dilworth‐Anderson, Peggye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549961/ https://www.ncbi.nlm.nih.gov/pubmed/37799322 http://dx.doi.org/10.1002/trc2.12426

Ejemplares similares

Open peer commentary on “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions”
por: Gandy, Sam
Publicado: (2023)

Immunotherapy for Alzheimer’s disease: hoops and hurdles
por: Lemere, Cynthia A
Publicado: (2013)

Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review
por: Gilmore-Bykovskyi, Andrea L., et al.
Publicado: (2019)

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
por: Frost, Jeffrey L., et al.
Publicado: (2012)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice
por: He, Ping, et al.
Publicado: (2007)

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
por: Schilling, Stephan, et al.
Publicado: (2018)

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
por: Cynis, Holger, et al.
Publicado: (2016)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
por: Weller, Roy O, et al.
Publicado: (2009)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models
por: Kumar, Sathish, et al.
Publicado: (2020)

Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Cohort Study
por: Wilkins, Consuelo H., et al.
Publicado: (2022)

Opportunities and challenges in public and community engagement: the connected for cognitive health in later life (CHILL) project
por: Lee, Caroline, et al.
Publicado: (2018)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
por: Yadollahikhales, Golnaz, et al.
Publicado: (2023)

A call to address structural barriers to Hispanic/Latino representation in clinical trials on Alzheimer's disease and related dementias: A micro‐meso‐macro perspective
por: Aranda, María P., et al.
Publicado: (2023)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Shared Decision Making Between Older Adult Home Health Patients and Their Caregivers: A Dyadic Coping Perspective
por: Tay, Djin, et al.
Publicado: (2020)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
por: Moreth, Jens, et al.
Publicado: (2013)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model
por: Dorostkar, Mario M., et al.
Publicado: (2014)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
por: Leurent, Claire, et al.
Publicado: (2019)

Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease
por: Bairamian, Diane, et al.
Publicado: (2022)

BrightFocus Alzheimer’s Fast Track 2019
por: Whitaker, Keith W., et al.
Publicado: (2019)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
por: Crespi, Gabriela A. N., et al.
Publicado: (2015)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

179. A Passive, Prescriber-Directed, Electronic Alert Plus Prescriber Education Decreased Antibiotic Prescribing for Ambulatory Adults With Acute, Uncomplicated Bronchitis in a Large Integrated Health System
por: Horvat, Courtney, et al.
Publicado: (2018)

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
por: Crehan, Helen, et al.
Publicado: (2020)

Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
por: DiFrancesco, Jacopo C., et al.
Publicado: (2015)

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
por: Bateman, Randall J, et al.
Publicado: (2011)

THE LEAD GUIDE: LIFE PLANNING IN EARLY ALZHEIMER’S AND DEMENTIA
por: Dassel, Kara B, et al.
Publicado: (2019)

Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy
por: Saito, Satoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2ohrhkoe5kkqf262qn8g7tsl10